PTJ
AMRX icon

Paul Tudor Jones’s Amneal Pharmaceuticals AMRX Stock Holding History

Paul Tudor Jones’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,288
Closed -$671K – 3555
2025
Q4 		$671K Sell
53,288
-38,722
-42% -$443K ﹤0.01% 2544
2025
Q3 		$921K Buy
+92,010
New +$826K ﹤0.01% 2328
2025
Q2 		– Sell
-152,304
Closed -$1.28M – 3205
2025
Q1 		$1.28M Buy
+152,304
New +$1.27M ﹤0.01% 1653
2021
Q2 		– Sell
-13,838
Closed -$93K – 1582
2021
Q1 		$93K Buy
+13,838
New +$76.7K ﹤0.01% 1490

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Paul Tudor Jones's AMRX Position: Q1 2026 in Review

Paul Tudor Jones sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 53,288 shares — an estimated $671K sold.

Paul Tudor Jones first reported a position in AMRX in Q1 2021 and held it in 4 quarters. The position peaked at $1.28M in Q1 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Paul Tudor Jones reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 53,288 Amneal Pharmaceuticals shares in Q1 2026, an estimated $671K.
  • Paul Tudor Jones first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Paul Tudor Jones's Amneal Pharmaceuticals position peaked at $1.28M in Q1 2025.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.